Companies House 15398252 2025-01-31 2025-01-31 2024-01-09 false iso4217:GBP xbrli:pure 15398252 2025-01-31 15398252 2024-01-09 2025-01-31 15398252 curr:PoundSterling 2024-01-09 2025-01-31 15398252 uk-bus:CompanyLimitedByGuarantee 2024-01-09 2025-01-31 15398252 uk-bus:FRS102 2024-01-09 2025-01-31 15398252 uk-bus:AuditExempt-NoAccountantsReport 2024-01-09 2025-01-31 15398252 uk-bus:FullAccounts 2024-01-09 2025-01-31 15398252 uk-bus:RegisteredOffice 2024-01-09 2025-01-31 15398252 uk-bus:Director1 2024-01-09 2025-01-31 15398252 uk-bus:Director2 2024-01-09 2025-01-31 15398252 uk-bus:Director3 2024-01-09 2025-01-31 15398252 uk-bus:Director4 2024-01-09 2025-01-31 15398252 uk-bus:Director5 2024-01-09 2025-01-31 15398252 uk-bus:Director6 2024-01-09 2025-01-31 15398252 uk-bus:Director7 2024-01-09 2025-01-31 15398252 uk-bus:Director8 2024-01-09 2025-01-31 15398252 uk-bus:Director9 2024-01-09 2025-01-31 15398252 uk-bus:Director10 2024-01-09 2025-01-31 15398252 uk-bus:Director11 2024-01-09 2025-01-31 15398252 uk-bus:Director12 2024-01-09 2025-01-31 15398252 uk-bus:Director13 2024-01-09 2025-01-31 15398252 uk-bus:Director14 2024-01-09 2025-01-31 15398252 uk-bus:Director15 2024-01-09 2025-01-31 15398252 uk-bus:Director16 2024-01-09 2025-01-31 15398252 uk-bus:Director17 2024-01-09 2025-01-31 15398252 uk-bus:Director18 2024-01-09 2025-01-31 15398252 uk-bus:Director19 2024-01-09 2025-01-31 15398252 uk-bus:Director20 2024-01-09 2025-01-31 15398252 uk-bus:Director21 2024-01-09 2025-01-31 15398252 uk-bus:CompanySecretary1 2024-01-09 2025-01-31 15398252 core:AfterOneYear 2025-01-31 15398252 core:WithinOneYear 2025-01-31 15398252 core:WithinOneYear 2024-01-09 2025-01-31 15398252 core:AfterOneYear 2025-01-31 15398252 core:AfterOneYear 2024-01-09 2025-01-31 15398252 core:ShareCapital 2025-01-31 15398252 core:SharePremium 2025-01-31 15398252 core:OtherReservesSubtotal 2025-01-31 15398252 core:RevaluationReserve 2025-01-31 15398252 core:RetainedEarningsAccumulatedLosses 2025-01-31 15398252 1 2024-01-09 2025-01-31 15398252 2 2024-01-09 2025-01-31 15398252 3 2024-01-09 2025-01-31 15398252 core:LandBuildings 2024-01-09 2025-01-31 15398252 core:LandBuildings 2025-01-31 15398252 core:PlantMachinery 2024-01-09 2025-01-31 15398252 core:PlantMachinery 2025-01-31 15398252 core:FurnitureFittingsToolsEquipment 2024-01-09 2025-01-31 15398252 core:FurnitureFittingsToolsEquipment 2025-01-31 15398252 core:OfficeEquipment 2024-01-09 2025-01-31 15398252 core:OfficeEquipment 2025-01-31 15398252 core:Vehicles 2024-01-09 2025-01-31 15398252 core:Vehicles 2025-01-31 15398252 core:NetGoodwill 2024-01-09 2025-01-31 15398252 core:NetGoodwill 2025-01-31 15398252 core:IntangibleAssetsOtherThanGoodwill 2024-01-09 2025-01-31 15398252 core:IntangibleAssetsOtherThanGoodwill 2025-01-31

# CEPEF CIC

## Company limited by guarantee

## Company Registration Number:
15398252 (England and Wales)

## Unaudited statutory accounts for the year ended 31 January 2025

## Period of accounts

## Start date: 9 January 2024

## End date: 31 January 2025

# CEPEF CIC

## Contents of the Financial Statements

for the Period Ended 31 January 2025

Profit and loss |
Balance sheet |
Additional notes |
Community Interest Report |

# CEPEF CIC

## Profit And Loss Account

for the Period Ended 31 January 2025

| 13 months to 31 January 2025
--- | ---
| £
Turnover: | 0 |
Cost of sales: | 0 |
Gross profit(or loss): | 0
Distribution costs: | 0 |
Administrative expenses: | 0 |
Other operating income: | 0 |
Operating profit(or loss): | 0
Interest receivable and similar income: | 0 |
Interest payable and similar charges: | 0 |
Profit(or loss) before tax: | 0
Tax: | 0 |
Profit(or loss) for the financial year: | 0

# CEPEF CIC

## Balance sheet

As at 31 January 2025

| Notes | 13 months to 31 January 2025
--- | --- | ---
|  | £
Fixed assets
Intangible assets: |  | 0 |
Tangible assets: |  | 0 |
Investments: |  | 0 |
Total fixed assets: |  | 0
Current assets
Stocks: |  | 0 |
Debtors: |  | 0 |
Cash at bank and in hand: |  | 0 |
Investments: |  | 0 |
Total current assets: |  | 0
Prepayments and accrued income: |  | 0 |
Creditors: amounts falling due within one year: |  | 0 |
Net current assets (liabilities): |  | 0
Total assets less current liabilities: |  | 0
Creditors: amounts falling due after more than one year: |  | 0 |
Provision for liabilities: |  | 0 |
Accruals and deferred income: |  | 0 |
Total net assets (liabilities): |  | 0
Members' funds
Profit and loss account: |  | 0 |
Total members' funds: |  | 0

The notes form part of these financial statements

# CEPEF CIC

## Balance sheet statements

For the year ending 31 January 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 9 October 2025
and signed on behalf of the board by:

Name: Dr G M Johnston
Status: Director

The notes form part of these financial statements

# CEPEF CIC

## Notes to the Financial Statements

for the Period Ended 31 January 2025

- ## 1. Accounting policies

  Basis of measurement and preparation

  These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

# CEPEF CIC

## Notes to the Financial Statements

for the Period Ended 31 January 2025

- ## 2. Employees

  | 13 months to 31 January 2025
  --- | ---
  Average number of employees during the period | 0 |

# COMMUNITY INTEREST ANNUAL REPORT

### CEPEF CIC

### Company Number: 15398252 (England and Wales)

### Year Ending: 31 January 2025

Company activities and impact

The Company was set up to continue to carry out epidemiological research into unexpected perioperative deaths in horses (the Confidential Enquiry into Perioperative Equine Fatalities) known by the abbreviation CEPEF. This research was started more than 20 years ago and led to a significant increase in the understanding about the prevalence of this outcome and the contributing risk factors. The Company holds the intellectual property of the methods of investigation and the results.

Consultation with stakeholders

The 4th phase of the study collected information about 8656 cases from 69 equine veterinary practices around the world.

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
9 October 2025

And signed on behalf of the board by:
Name: Dr. G M Johnston
Status: Director